Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

"All three types of myasthenia gravis, based on antibody status, can have similar symptoms," said Henry Kaminski, MD, of George Washington University in Washington, D.C. "Most patients have droopy ...

This article provides a thorough overview of the pathophysiology and current treatment options for myasthenia gravis, an autoimmune and antibody-mediated neuromuscular disease.

A retrospective analysis of patients with acetylcholine receptor antibody (AChR-Ab)-positive generalized myasthenia gravis (MG) who underwent thymectomy found that a majority of them had good long ...

8. Country-Specific Patient Population of Myasthenia Gravis 9. Myasthenia Gravis Current Treatment and Medical Practices 10. Myasthenia Gravis Unmet Needs 11. Myasthenia Gravis Emerging Therapies 12.